Low Pretreatment CALLY Index Predicts Early Recurrence in Resected UICC Stage I Pancreatic Ductal Adenocarcinoma.

Q3 Medicine

Tokai Journal of Experimental and Clinical Medicine Pub Date : 2025-04-20

Taro Mashiko, Toshihito Ogasawara, Yoshihito Masuoka, Shigenori Ei, Shinichiro Takahashi, Masaki Mori, Kazuo Koyanagi, Seiichiro Yamamoto, Toshio Nakagohri

{"title":"Low Pretreatment CALLY Index Predicts Early Recurrence in Resected UICC Stage I Pancreatic Ductal Adenocarcinoma.","authors":"Taro Mashiko, Toshihito Ogasawara, Yoshihito Masuoka, Shigenori Ei, Shinichiro Takahashi, Masaki Mori, Kazuo Koyanagi, Seiichiro Yamamoto, Toshio Nakagohri","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: We aimed to identify the inflammation-based prognostic score (IBPS) that can be used to predict the recurrence of early-stage pancreatic ductal carcinoma (PDAC).Methods: In this retrospective study, the data of 109 patients with Union for International Cancer Control (UICC) stage I PDAC who underwent pancreatectomy between January 2005 and December 2020 at Tokai University Hospital were assessed. The clinicopathological and risk factors for early recurrence were compared between the early (within 12 postoperative months) recurrence (ER) group (n = 29) and non-ER group (n = 80).Results: The median overall survival (OS) durations of the ER and non-ER groups were 15.0 (95% confidence interval [CI]: 8.0-22.0) and 109.0 (95% CI: 91.4-120.9) months, respectively (p < 0.001). The patients in the ER group had a significantly poorer prognosis. Multivariate analysis showed that the C-reactive protein-albumin-lymphocyte (CALLY) index ( < 4.4) (hazard ratio [HR]: 2.71, 95% CI: 1.21-6.02]), positive venous invasion (HR: 4.67, 95% CI: 1.10-19.90), tumor differentiation (moderately/poorly) (HR: 2.25, 95% CI: 2.05-13.43), and failure to complete adjuvant chemotherapy (HR: 12.50, 95% CI: 5.30-29.50) were independent risk factors for early recurrence.Conclusions: Low pretreatment CALLY index was a useful predictor of early recurrence in patients with UICC stage I PDAC.","PeriodicalId":38819,"journal":{"name":"Tokai Journal of Experimental and Clinical Medicine","volume":"50 1","pages":"25-33"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tokai Journal of Experimental and Clinical Medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We aimed to identify the inflammation-based prognostic score (IBPS) that can be used to predict the recurrence of early-stage pancreatic ductal carcinoma (PDAC).

Methods: In this retrospective study, the data of 109 patients with Union for International Cancer Control (UICC) stage I PDAC who underwent pancreatectomy between January 2005 and December 2020 at Tokai University Hospital were assessed. The clinicopathological and risk factors for early recurrence were compared between the early (within 12 postoperative months) recurrence (ER) group (n = 29) and non-ER group (n = 80).

Results: The median overall survival (OS) durations of the ER and non-ER groups were 15.0 (95% confidence interval [CI]: 8.0-22.0) and 109.0 (95% CI: 91.4-120.9) months, respectively (p < 0.001). The patients in the ER group had a significantly poorer prognosis. Multivariate analysis showed that the C-reactive protein-albumin-lymphocyte (CALLY) index ( < 4.4) (hazard ratio [HR]: 2.71, 95% CI: 1.21-6.02]), positive venous invasion (HR: 4.67, 95% CI: 1.10-19.90), tumor differentiation (moderately/poorly) (HR: 2.25, 95% CI: 2.05-13.43), and failure to complete adjuvant chemotherapy (HR: 12.50, 95% CI: 5.30-29.50) were independent risk factors for early recurrence.

Conclusions: Low pretreatment CALLY index was a useful predictor of early recurrence in patients with UICC stage I PDAC.

本刊更多论文

低预处理CALLY指数预测切除的UICC期胰管腺癌早期复发。

目的：我们旨在确定炎症预后评分（IBPS）可用于预测早期胰导管癌（PDAC）复发。方法：在这项回顾性研究中，对2005年1月至2020年12月在东海大学医院接受胰腺切除术的109例国际癌症控制联盟（UICC） I期PDAC患者的数据进行评估。比较早期（术后12个月内）复发（ER）组（n = 29）和非ER组（n = 80）早期复发的临床病理及危险因素。结果：ER组和非ER组的中位总生存期（OS）分别为15.0个月（95%可信区间[CI]: 8.0-22.0）和109.0个月（95% CI: 91.4-120.9），差异有统计学意义（p < 0.001）。ER组患者预后明显较差。多因素分析显示，c反应蛋白-白蛋白淋巴细胞（CALLY）指数（< 4.4）（危险比[HR]: 2.71, 95% CI: 1.21-6.02]）、静脉浸润阳性（HR: 4.67, 95% CI: 1.10-19.90）、肿瘤分化（中度/重度）（HR: 2.25, 95% CI: 2.05-13.43）、未能完成辅助化疗（HR: 12.50, 95% CI: 5.30-29.50）是早期复发的独立危险因素。结论：低预处理CALLY指数是UICC I期PDAC患者早期复发的有效预测指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tokai Journal of Experimental and Clinical Medicine Medicine-Medicine (all)

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： The Tokai Journal of Experimental and Clinical Medicine, also referred to as Tokai Journal, is an official quarterly publication of the Tokai Medical Association. Tokai Journal publishes original articles that deal with issues of clinical, experimental, socioeconomic, cultural and/or historical importance to medical science and related fields. Manuscripts may be submitted as full-length Original Articles or Brief Communications. Tokai Journal also publishes reviews and symposium proceedings. Articles accepted for publication in Tokai Journal cannot be reproduced elsewhere without written permission from the Tokai Medical Association. In addition, Tokai Journal will not be held responsible for the opinions of the authors expressed in the published articles.